11 November 2022 Pre-release EU-SRS

# Human Vaccines EU-SRS User Guide

Guidance on the naming and building of human vaccine substance records in EU-SRS

#### Disclaimer

This document is created as part of deliverable D2.8 EU-SRS Data Management Plan of Unicom Work Package 2: Implement IDMP – Substance Management in Europe.

This guide will be a living document, used by the Substances Validation Group (SVG) for creation and maintenance of substances in EU-SRS.

The current version is a pre-release. Your feedback, if any, is welcomed by **8 December 2022.** Comments can be sent to Steven de Wit (e-mail: <u>s.d.wit@cbg-meb.nl</u>).

Your feedback will be considered when preparing the official release which will be submitted as Unicom deliverable to the European Commission in January 2023.

## **Document control**

This document is subject to a regular review by the Substance Validation Group (SVG). It is a living document, and changes will be captured in the version history section.

#### **Document ownership**

This document is owned by the SVG.

#### **Revision history**

Version	Date	Changes made	Author(s)
N/A	11.11.2022	Pre-release	Olof Lagerlund, Corma Otte, Marcel Hoefnagel, Emelie Ahnfelt

# TABLE OF CONTENTS

D	ocum	ento	control	2	
	Document ownership2				
	Revi	sion	history	2	
Li	st of a	abbr	eviations	5	
1	Int	rodu	iction	6	
	1.1	Pu	rpose	6	
	1.2	Sco	ope	6	
	1.3	Lin	k between EU-SRS and SMS	6	
2	De	finin	g a Human Vaccine Substance	7	
	2.1	ΕU	-SRS hierarchy	7	
3	Na	ming	g of Human Vaccines	8	
	3.1	Aco	ceptable sources for naming of human vaccines substances	8	
	3.2	Na	me types	8	
	3.2	2.1	Jurisdiction	9	
	3.3	Na	ming hierarchy	9	
	3.4	Na	ming syntax	9	
	3.4	4.1	Preferred term and Aliases	9	
	3.4	1.2	Syntax for the Preferred term for conventional vaccines	9	
	3.5	No	n-conventional vaccines – information on strain level1	1	
	3.5	5.1	Vaccines using deletion mutants1	1	
	3.5	5.2	Viral vector vaccines	1	
	3.5	5.3	DNA vaccines1	2	
	3.5	5.4	Other types (placeholder) 1	2	
4	Bu	ildin	g Human Vaccine Records1	3	
	4.1	Ne	w entry1	3	
	4.2	Re	ferences1	6	
5	Ар	pen	dices1	7	
	5.1	ΕU	-SRS Field Guide1	7	
	5.1	1.1	EU-SRS field guidance 1	7	
	5.2	Hu	man vaccine data field overview EU-SRS Examples (placeholder) 2	2	

# LIST OF FIGURES

Figure	1 Example of	a hierarchy in F	U-SRS	7
. igaio	n Example of			 •••••••••••••••••

# LIST OF TABLES

Table 1. Accepted sources for naming vaccine substances.	. 8
Table 2. High level steps to register a human vaccine substance at author level	13

# List of abbreviations

Abbreviation	Complete Form
CV	Controlled Vocabulary
EMA	European Medicines Agency
EP	European Pharmacopoeia
EU	European
EU-SRS	European Substance Registration System
ICTV	International Committee on Taxonomy of Viruses
INN	International Non-proprietary Name
ISO IDMP	International Organization of Standardization Identification of Medicinal Products
ITIS	Integrated Taxonomic Information System
LSPN	List of Prokaryotic names with Standing in Nomenclature
MAH	Market Authorization Holder
mRNA	messenger Ribonucleic Acid
NCBI	National Centre for Biotechnology Information
NCI	National Cancer Institute
PT	Preferred Term
SmPC	Summary of Product Characteristics
SMS	Substance Management Services
SPOR	Substances, Products, Organizations, Referentials (EMA)
SSG1	Specified Substance Group 1
SVG	Substance Validation Group

## 1 Introduction

The EU Network is currently implementing the ISO IDMP standards in a phased programme based on the four domains of master data in pharmaceutical regulatory processes: substance, product, organisation and referential (collectively referred to as "SPOR") master data. ISO IDMP compliant business services for the central management and supervision of data in each of the four SPOR areas will be established through an iterative and incremental delivery approach. Through the Substance Management Services (SMS) of the SPOR programme EMA will provide the EU network centralised substance data management services.

The European Substance Registration System (EU-SRS) will become the scientifically rigorous backend for the Substance Management Services (SMS) of SPOR. EU-SRS will be accessible by the EU regulatory network, enabling the unambiguous identification of substances used in medicinal products based on their scientific properties in accordance with ISO IDMP standard 11238 and ISO IDMP technical specification standard 19844. EU-SRS allows the unique identification of substances which will support various purposes including the enhancement of traceability of pharmacovigilance, nonclinical, clinical and quality findings with a high degree of precision to substances by their scientific identity.

The Substance Validation Group (SVG) is responsible for the data entry of substance records in EU-SRS. In addition, the SVG defines guidance and best practices for substances management in EU-SRS (per substance type).

#### 1.1 Purpose

The purpose of this document is to provide practical guidance regarding naming and building of human vaccine substance records in EU-SRS.

#### 1.2 Scope

Naming rules and building guidance for human vaccine substances in EU-SRS are in scope of this document. This document is to be used together with the general EU-SRS Substance Maintenance Process document/ which describes in detail the workflow between EMA and SVG (under development).

#### 1.3 Link between EU-SRS and SMS

Vaccine substance harmonisation between SMS and EU-SRS is planned for 2023.

## 2 Defining a Human Vaccine Substance

The scope of this document is the human medicinal products commonly described as vaccines. The definition of a 'Vaccine', according to ISO/TS 19844:2017 Annex I (I3.4), is:

'A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins.'

Conventional vaccines refer to live, attenuated, or inactivated vaccines. In recent days, nonconventional vaccines have generated an increased interest. Examples of non-conventional vaccines are mRNA-, DNA-, and viral vector vaccines.

#### 2.1 EU-SRS hierarchy

EU-SRS provides the opportunity to establish relationships between the records and therefore a hierarchy can be built. This hierarchy consists of three levels:

- Scientific name/Author level (highest level, mandatory)
  - Serovar/Serogroup/Serotype level (middle level, if applicable)
     Strain/Fraction level (lowest level, mandatory)

The records regarding one substance are interlinked in the hierarchy. One record at the scientific/author level may have many records at the levels below.

An example on the hierarchy is provided in Error! Reference source not found..



Figure 1. Example of a hierarchy in EU-SRS.

## 3 Naming of Human Vaccines

This chapter provides details around the naming of vaccines in EU-SRS. Detailed instructions regarding the building of records in EU-SRS as well as detailed field definitions can be found in section 4 and the appendices (section **Error! Reference source not found.**).

#### 3.1 Acceptable sources for naming of human vaccines substances

All names must have at least one public reference. Accepted sources for naming vaccines are listed in Table 1. The reference may be a publicly available database or an authorized naming body, see Table 1. For human vaccines, not all substances can be found in scientific public sources. In that case, the SmPC can be cited as a source. The Official naming bodies (for example INN) are listed in the General EU-SRS User Guide, which will be published at a later stage.

Name	Hyperlink
National Centre for Biotechnology Information (NCBI)	https://www.ncbi.nlm.nih.gov/Taxonomy/Brows er/wwwtax.cgi)
International Committee on Taxonomy of Viruses (ICTV)	https://talk.ictvonline.org/taxonomy/
Integrated Taxonomic Information System (ITIS)	https://www.itis.gov
European Pharmacopoeia	https://pheur.edqm.eu/home
List of Prokaryotic names with Standing in Nomenclature (LPSN)	https://lpsn.dsmz.de/
SmPC (in case all other public sources fail)	NA

**Table 1.** Accepted sources for naming vaccine substances.

#### 3.2 Name types

All records in the EU-SRS system will contain name type information which is chosen from a drop-down list. The Name types used for vaccine substances are.

- Official Name: Reflects the organization that assigns or recognizes the name associated with the substance. These names are typically non-proprietary names that are used in the labelling of pharmaceuticals. The domains and jurisdictions in which the official name is used are also captured, tracked, and maintained within the terminology.
- **Common Name**: Any other name or synonym.
- **Code:** Company Code/name for a substance provided in an early stage of development.
- Scientific name: is based on the biological taxonomic nomenclature and reflects the current scientific knowledge based on acknowledged scientific/ taxonomic databases, which are however no official naming bodies (no jurisdiction applies) applicable for naming species of organisms (including e.g. microorganisms, plants and viruses).

#### 3.2.1 Jurisdiction

In case of selecting 'Official Name' as Name type, an additional field 'Naming Organizations' is available, where the respective Naming Organization should be included. A full list of acceptable naming organizations and jurisdiction can be found in the General EU-SRS User Guide.

**Table 3.** Acceptable Official Naming Organizations relevant for vaccines and jurisdiction.

Name	Jurisdiction
International Non-proprietary Name (INN)	EU
European Pharmacopoeia (EP)	EU

#### 3.3 Naming hierarchy

The use of EU-SRS provides the opportunity to establish relationships between the pathogen and related vaccine substances via a hierarchy consisting of three vaccine syntax levels. The pathogen is represented at the highest hierarchy level – (1) the scientific/author level – and may have several records linked on (2) serovar (if applicable) and (3) strain levels. Information regarding if the vaccine is live, attenuated, inactivated or modified should be included on Strain level. An additional SSG1 level, with for example adjuvant information can also be added in the hierarchy.

#### 3.4 Naming syntax

The vaccine syntax is described and will consider bacteria, viruses and parasites. If the active substance is a recombinant or purified protein (a 'Fraction'), the syntax used conforms to the respective parent organism. Capitalization of pathogen names will follow formal taxonomic rules and other syntax groups will begin with an upper case.

#### 3.4.1 **Preferred term and Aliases**

One substance can have several names but the preferred term (PT) in EU-SRS is usually based on the scientific name in accordance with the ISO 11238/TS19844. The PT is independent of level and is also the Display name. Syntax details for the three levels are provided below. Other relevant names can be included as aliases in EU-SRS. In case there is a need to differentiate between MAH between similar products, which can't be separated on a name level due to confidentiality, the MAH name will be added to the PT at the end of the syntax.

#### 3.4.2 Syntax for the Preferred term for conventional vaccines

The syntax for the three levels will reflect the source material. On the scientific/author level, information related to source material is captured. When the complete organism is the source the substance name also includes the 'Part' or 'Whole'. The PT is based on the author level name in combination with the serovar/serogroup/serotype for bacteria and viruses or species in the case of parasites. The Strain/fraction level refers to a genetic variant, modification or subtype describing the antigen and may include additional information such as MAH.

The list of antigen types currently in use are listed below.

Bacterium, Whole, Inactivated Bacterium, Whole, Live, Attenuated mRNA Polymer (polysaccharide) Polymer (polysaccharide) conjugated to carrier protein Polymer (polysaccharide) conjugated to toxoid Polymer (polysaccharide) conjugated to toxoid adsorbed to Aluminium Polymer conjugated to carrier protein adsorbed to Aluminium Protein Protein adsorbed on Aluminium Protein adsorbed on Aluminiumhydroxide Toxoid Toxoid adsorbed on Aluminium Virus, Live Whole. Chimeric, Recombinant Virus, Whole, Live, Attenuated Virus, Whole, Live, Recombinant Virus, Whole, Inactivated Virus, Whole, Inactivated adsorbed on Aluminium

Syntax Author level:

Bacteria: <Microorganism name>, <(Primary) secondary author>, <Year>, <Part> Virus: <Microorganism name>, <Part>

Parasites: Microorganism name>, <(Primary) secondary author>, <Year>, <Part>

Syntax Serovar level:

Bacteria: <Microorganism name>, <Serovar/ Serogroup/ Serotype>, <Part>

Virus <Microorganism name>, <Serovar/ Serogroup/ Serotype>, <Part>

Parasite: <Microorganism name>, <Species>, <Part>

Syntax Strain level:

Bacteria: <Microorganism name>, <Serogroup/Serovar/Serotype>, <Strain>, <Antigen>, <Part>, <Status>

Virus <Microorganism name>, <Serogroup/Serovar/Serotype>, <Strain>, <Antigen\*>, <Part>, <Status>

Parasite: <Microorganism name>, <Species>, <Strain>, <Antigen>, <Part>, <Status>

#### 3.5 Non-conventional vaccines – information on strain level

Non-conventional vaccines often follow the approach for the conventional vaccines up to strain level. Information on strain level differs between the non-conventional vaccines and is visible in the syntax, where any genetic modifications should be described between <strain> and <status>. See details for the specific vaccines below.

Syntax (Preferred term):

<Microorganism name>, <Serogroup/Serovar/Serotype>, <Strain>, <Antigen>, <Part>, <Status>

#### 3.5.1 Vaccines using deletion mutants

For vaccines using deletion mutants the strain may include modification information and Status will include modification e.g. Inactivation.

Syntax (Preferred term):

<Microorganism name>, <Serogroup/Serovar/Serotype>, <Serovar>, <Strain>, <Modification>, <Part>, <Status>

#### 3.5.2 Viral vector vaccines

Syntax (Preferred term):

<Vector>, <Strain>, <Inserted microorganism>, <Antigen>, <Part>, <Status>

#### 3.5.3 DNA vaccines

If no DNA sequence is available, then a 'Structurally Diverse' record should be created and may be later a 'Nucleic acid 'Alternative definition' record can be attached.

Syntax (Preferred term):

<Parent strain name>, <DNA used as active substance>, <Part>, <Status>

### 3.5.4 Other types (placeholder)

Syntax (Preferred term):

<Parent strain name>, <placeholder>, <Part>, <Status>

# 4 Building Human Vaccine Records

## 4.1 New entry

Table 2.	High	level ste	eps to r	egister a	human	vaccine	substance	at author	level.

Step	Activity	Step action
Step 1	Collect information	<ul> <li>Open the dossier of the vaccine that you want to build in EU-SRS.</li> <li>Information is needed on: <ul> <li>Name of the marketed product</li> <li>Which pathogen is the vaccine used for?</li> <li>Active substance: is it a virus, bacterium, parasite, polymer, protein, mRNA etc.?</li> <li>What are the specifics of the virus (e.g. strain), bacterium (e.g. serovar), etc?</li> <li>If the virus/bacterium/ is inactivated, look for information on how this is done (formaldehyde, β-Propiolactone, heat, etc); you will need details on concentration of the inactivating agent, time of inactivation, temperature, etc.</li> </ul> </li> <li>You will need REFERENCES to substantiate your records, so look for definitions in NCBI taxonomy, NCI thesaurus, scientific papers, etc. to find information on the virus/bacterium/parasite.</li> <li>Save the scientific papers since they can be linked to the record</li> <li>Write down the NCBI taxonomy/NCI thesaurus numbers to use in CODES</li> <li>The information you gather can be easily displayed in a WORD document where you can add relevant parts from dossier sections, NCBI numbers, information from scientific articles, etc.</li> </ul> <li>If needed (e.g. to add additional information), you can always EDIT THE RECORD (use the pencil icon) after it has been saved to add more information or change the information already present.</li>
Step 2	Search Substance	<ul> <li>Is the Author Level already present in EU-SRS?</li> <li>Search via SEARCH SUBSTANCES (top right), start typing and a list with suggestions will be displayed at the bottom of the SEARCH field</li> <li>Be careful to select the EU entries and not the USA entries. USA entries can be recognised by their NAME in CAPITALS</li> </ul>

Step	Activity	Step action
		and the presence of a <b>red number</b> in the top right-hand corner. <b>Yes</b> : finalize the record according to the steps below <b>No</b> : create the record from the start, see below under CREATE NEW RECORD
FINALIZE 1	THE RECORD	RECORD
Step 3	Adjust Substance Type	Some records are present as CONCEPTS. In that case, the SUBSTANCE TYPE needs to be changed to STRUCTURALLY DIVERSE:
		➔ You will need ADMIN RIGHTS for this
		<ul> <li>Open the CONCEPT, click on the pencil icon to EDIT, select ADVANCED FEATURES (top middle), select CHANGE SUBSTANCE CLASS, select NEW CLASS, STRUCTURALLY DIVERSE</li> </ul>
		Fill out the required fields, such as NAMES, CODES, REFERENCES, etc and VALIDATE AND SUBMIT (top right)
		➔ Sometimes you will find that a DROP-DOWN list with values (named CV in EU-SRS) opens when you start typing in a field.
		→ The warning messages will tell you what is happening with your record
		<ul> <li>RED WARNING: you cannot save the record and need to fix the problem that is stated</li> <li>ORANGE warning: you can DISMISS this warning and</li> </ul>
		<ul> <li>GREEN warning: this record can be saved immediately</li> </ul>
	NEW RECORD	
Step 3	diverse	If the record, you need for your vaccine is not already present build a new record in EU-SRS.
		<ul> <li>Select REGISTER, STRUCTURALLY DIVERSE (top left)</li> <li>Fill out the OVERVIEW and add a DEFINITIONAL REFERENCE by using the CREATE NEW (+) button</li> </ul>
		➔ If a record is no longer valid, tick the DEPRECATED box; you will not need this when building a vaccine, but it may be useful if your vaccine is BLOCKED by the system. You can then DEPRECATE the blocking record and continue building your record.

Step	Activity	Step action
		➔ You can open multiple instances of EU-SRS on different screens so you can DEPRECATE an old record in one instance while continue your building process in the second instance.
		<ul> <li>Add a NAME by selecting ADD NAMES (+)         <ul> <li>Always register an OFFICIAL NAME and tick the DN circle on the left</li> <li>Select the drop-down arrow next to MORE (top right in NAMES) and fill out DOMAINS (biologic and Hum. Vac) and JURISDICTION (European union)</li> <li>Add a REFERENCE</li> </ul> </li> <li>Multiple names could be added in this way, for example a COMMON NAME; then tick the AL square on the left; only 1 record can be OFFICIAL AND DN</li> <li>Fill out SOURCE MATERIAL (SOURCE MATERIAL CLASS = ORGANISM, SOURCE MATERIAL TYPE = BACTERIUM/VIRUS/PARASITE/, for the AUTHOR LEVEL, we always choose WHOLE)</li> <li>Add ORGANISM DETAILS (FAMILY, GENUS, SPECIES, AUTHOR (if applicable), DEVELOPMENTAL STAGE (if applicable))</li> <li>Add CODES (these are the NCBI TAXONOMY NUMBER, NCI THESAURUS NUMBER, VACCINE NAME, etc)</li> </ul>

The steps in Table 4 can be repeated to build other records, such as a VIRUS STRAIN (structurally diverse) and a MODIFIED VIRUS STRAIN (SSG1), e.g. an inactivated strain. Please note that the SSG1 (or G1SS) level will contain confidential information. It is also possible to create PROTEINS as (part of) a vaccine substance (please refer to the PROTEIN GUIDE).

These records can then be LINKED to the author level. This will result in a hierarchy where all the strains belonging to a parent organism can be seen in an overview. An example of a vaccine record is provided in **Error! Reference source not found.** 



<u>Meisseria neningitidis, Serogroup A, Whole-CO-EX</u> 🔒			
STRUCTURALLY DIVERSE Names: Meisseria neningitidis, Serogroup A, Whole-CO-EX V	Created:	12/17/21	
	Created By:		
	Status:	pending	
	Last Modified:	12/17/21	
GSKS-ID : UN665P604A	Last Modified	By.	
Relationships: 1	Version:	1	
Part: WHOLE			
Meisseria neningitidis (Hoetnagel and Diederik, 1981) Corazon, 1989, Whole-CO-EX		PENDING RECORD	
Meisseria neningitidis, Serogroup W135, Whole-CO-EX 🧨		PENDING RECORD	
Meisseria neningitidis, Serogroup Y, Whole-CO-EX 🧪		PENDING RECORD	
Meisseria neningitidis, Serogroup A, Whole-CO-EX		PENDING RECORD	
Meisseria neningiditis, Serogroup A, Strain C11, Polysaccharide-CO-EX 🧪		PENDING RECORD	
Meisseria neningitidis, Serogroup A, Strain C11, Oligosaccharide C.diphtheriae CRM197 Conjugated Antigen-CO-EX	1	PENDING RECORD	
Meisseria neningitidis, Serogroup A, Strain C11, Oligosaccharide C.diphtheriae CRM197 Conjugated Antigen, Ad-	sorbed on Aluminium 🧨	I	PENDING RECORD {G1SS}
> Meisseria neningitidis, Serogroup B, Whole-CO-EX		PENDING RECORD	
Meisseria neningitidis, Serogroup C, Whole-CO-EX 🧪		PENDING RECORD	
Meisseria neningitidis, serogroup B, Strain M98 250771, FHBP (Factor Heparin Binding Protein) subfamily A recombinant lip	1	PENDING RECORD	

Figure 2. Example of a hierarchy in EU-SRS.

#### 4.2 References

When building a vaccine in EU-SRS the "PUBLIC\_DOMAIN\_RELEASE" tag must be populated to make the record public. In general, the SmPC should contain this information. Once a reference is added to a record the references can be reused by selecting the tick box. Independently of the "PUBLIC\_DOMAIN\_RELEASE" tag, names can be marked as public using the tick box "Public Domain". This is specific for this name and has no influence on the accessibility of the whole record.

# 5 Appendices

#### 5.1 EU-SRS Field Guide

This section lists all EU-SRS fields and provides an explanation what rules apply to each field and when a certain field is used.

## 5.1.1 EU-SRS field guidance

EU-SRS field name	Field details
Overview	
Display Name	Automatically filled in from name section, OFFICIAL NAME, DN.
Record Level Access	Public or Restricted (standard = Public).
Deprecated	Relevant for a Deprecated Record. If a record is no longer valid this box should be ticked
Definition Type	Always Primary.
Definition Level	Always Complete.
Definitional References	Field linked to References
Names	
Name (Display Name/Preferred Term in EU- SRS)	Each record needs an 'Official Name' (TYPE which should be a scientifically correct name It is the Scientific/ taxonomic name, which is in 'English-Latin' and includes the Part (WHOLE, FRACTION). The Status is included with the value 'Inactivated' if applicable since 'Whole' is implicit the live organism. Mandatory details: Language = 'English', -tick DN circle, -choose Domains 'biologic' and 'Hum. Vac.', -choose a naming organisation ('Naming Organizations'), add a PUBLIC REFERENCE. -Jurisdiction = European Union Further detailed information on the single fields can be found below.
Name (Additional name)	Additional names (e.g., name type 'Common Name') can be included in the record. At least one reference is needed per name. Mandatory details: -language = English -tick 'AL square
Туре	An OFFICIAL NAME is mandatory (from e.g. ITIS, NCBI, ICTV, Ph. Eur., INN.)



EU-SRS field name	Field details	
Access	If the information in the record is confidential, Access can be set to 'PROTECTED'.	
Languages	If the name is in Latin, Language = English.	
DN circle	Tick box to indicate what name should be the Display Name in EU-SRS .	
AL square	Field is mandatory for the SMS-PT (not to be ticked for other aliases) and only needed if the EU-SRS PT differs from SMS-PT.	
Naming Organization (Name orgs)	see TYPE for naming organisations.	
Name Jurisdiction	EUROPEAN UNION	
Domain	Field is mandatory (and only included in the official name) - choose Domain 'biologic' and 'Hum. Vac.'.	
References	At least one public reference is needed per name.	
Concept upgrade		
Concept Upgrade	Choose the respective Substance Type (mostly 'Structurally Diverse'). The site will then be reloaded, and new fields appear (please see table 'EU-SRS field guidance for editing a Structurally Diverse'). See table 4 for details on how to change a concept to structurally diverse.	
Source Material		
Source Material Class	Organism'	
Source Material Type	Field is conditional. Choose one (in most cases Bacterium, Virus or Parasite).	
Source Material State	Live/Attenuated/Killed	
Source Material Record Type		
Whole / Part / Fraction	Default is 'Whole'. 'Part/Fraction' not applicable on author level but may be on other levels.	
Organism Details		
Organism Family	Field is mandatory.	
Organism Genus	Field is optional.	
Organism Species	This should come from ITIS or NCBI.	
Organism Author	Mandatory on Author level (except for a virus). Copy taxonomic database for name.	
Developmental Stage	Field is optional. (Might be relevant for some vaccines.)	
Infraspecific Type	Not applicable.	



EU-SRS field name	Field details
Infraspecific Name	Not applicable.
Agent Modifications	
Agent substance	Might be something like formaldehyde (for inactivation); might be aluminium hydroxide for adsorption
Modification process	Formaldehyde is an inactivation agent; aluminium hydroxide is for adsorption
Modification type	Formaldehyde is an inactivation agent (not a typo, same as modification process); aluminium hydroxide is for adsorption
Modification role	Formaldehyde is a crosslinker; aluminium hydroxide is an adsorbent agent
Amount	Fill in the amount of formaldehyde, the time formaldehyde may work on the vaccine bulk and the temperature at which the bulk is kept during inactivation. The amount may be in mg/ml, % w/w, etc.; same for aluminium hydroxide
Codes	
Code system	Fill in the NCBI taxonomy reference number, the NCI thesaurus number reference, the vaccine name; use the appropriate code system, e.g. NCBI, NCI, CBG dossier, EMA list, EMA EPAR, etc.
Code System Type	This is a default value (automatically filled in and managed by Admin).
Туре	In nearly all cases default 'Primary'. When the code is tied to the group use 'General'.
Code	Your text
URL	This field is conditional: Mandatory for NCBI Taxonomy and ITIS (copy the URL),
References	Fill in the references, e.g. NCBI, NCI, CBG dossier, EMA list, etc.
Code Text	This field is optional and useful to describe a definition used in the source (e.g., Ph. Eur.) or other relevant information.
Access	Set to Public
Relationships	
Related Substance	<i>This section could be used for creating a different type of relationship to the active moiety.</i>
References	Fill out the reference; references may be REUSED
Type (purpose hierarchy)	PARENT-> INFRASPECIFIC
Access	Public or restricted
Qualification	Not applicable.
Interaction Type	Not applicable.

EU-SRS field name	Field details
Amount	Fill out the Type (mol ratio, weight ratio or other, for example a %), Average (100% in case where the vaccine consists of this parent strain), references may be REUSED
Mediator Substance	Not applicable.
Comments	May be used
Notes	
Note	Field is optional and automatically populated by the system. System messages may be deleted (you will see many validation messages appearing here).
References	Field is optional.
Access	Not applicable
References	
Source Type	Drop-down list (CV-List); Mandatory field; Other (new value) may be used if the source type is not in the list
Source text	Mandatory field and should represent the related value of the type, e.g., the headline mentioned in the ITIS record.
Public Domain	Default is Public (Tick box), but it may be set 'Non-Public' in combination with a public reference. NOTE: a public reference is mandatory for a record, you cannot create a record with only NON_PUBLIC references
Access	Default is Open. Protected = confidential
URL	Fill in the URL for the reference, may be left blank
Source Id	Should have the Code of the Source Type
Upload a Document	This field is optional, scientific papers may be added here
Tags	This field should be populated by at least one value ('Public domain release') and if applicable other values.

Parent Organism Details- only displayed if 'Part/Fraction' is chosen		
Source Material Parent	Field is conditional. It is necessary to delete the Organism details populated in the 'Whole' mode of the record because reference is made to this information in the selected 'Parent organism'.	
Parts And Fractions – only displayed if 'Part/Fraction' was chosen		
Part	This field is optional for a certain type of vaccine, in most cases capsule or cell wall.	
Part Location	Not applicable.	

Fraction Name	This field is conditional for a certain type of vaccine (e.g., toxin).
Fraction Material Type	This field is conditional for a certain type of vaccine (e.g., protein).
Structural Modifications	
Modification Type	Optional at strain level for certain types of vaccines, in most cases proteins or polysaccharides.
Fragment	Optional at strain level for certain types of vaccines. The structure must be present in EU-SRS or should be pre-registered.
Location Type	Optional at strain level for certain types of vaccines, in most cases partial or complete.
Extent	Optional at strain level for certain types of vaccines.
Group	Not applicable.
Access	Optional at strain level for certain types of vaccines (Yes or Not Protected information).
Physical Modifications	
Modification Role	Optional at strain level for certain types of vaccines. To be used in e.g. heat inactivated material.
Parameters: Parameter Name	Optional at strain level for certain types of vaccines.
Parameters: Amount	Optional at strain level for certain types of vaccines.
Properties	
Name	Optional for certain types of vaccines, e.g., to be used in stability registration or Inactivation conditions other than Physical modifications.
Property Type	Optional for certain types of vaccines.
Amount	Optional for certain types of vaccines.
Parameter: Name	Optional for certain types of vaccines.
Parameter: Type	Optional for certain types of vaccines.
Parameter: Amount (see above)	Optional for certain types of vaccines.
Referenced Substance	Optional for certain types of vaccines.
Defining	Optional for certain types of vaccines, conditional for certain properties.
References	Optional for certain types of vaccines.
Access	Optional for certain types of vaccines.

## 5.2 Human vaccine data field overview EU-SRS Examples (placeholder)